Compare IDEXX Laboratories, Inc. (IDXX) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Impinj Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571.23 (market cap $46.22B), while Impinj Inc trades at $179.06 (market cap $5.32B). The key difference: IDEXX Laboratories, Inc. is far larger — about 8.7× Impinj Inc's market cap, and Impinj Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | PI | |
|---|---|---|
Market Cap | $46.22B | $5.32B |
Sector | Health | Technology |
52-Week High | $766.68 | $241.91 |
52-Week Low | $526.44 | $91.34 |
Enterprise Value | $47.12B | $5.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Impinj (PI) trades at $177.33, up 0.61% with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported record Q2 2026 revenue and earnings beats, though profitability remains negative with -7.26% net margins. Recent news highlights institutional accumulation and positive earnings momentum despite insider selling activity.
The stock offers growth potential from RFID market leadership and strong quarterly performance, but faces risks from negative profitability, high valuation multiples, and concentrated revenue streams. Analyst consensus remains strongly bullish with a $186 price target, representing 4.9% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
